Cole Davidson

Dr. Cole Davidson

University of Vermont
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Cole DavidsonCole Davidson
Cole Davidson
NGNoelle E. Gillis
Noelle E. Gillis
FCFrances Carr
Frances Carr
There is compelling evidence that the nuclear receptor TRβ, a member of the thyroid hormone receptor (TR) family, is a tumor suppressor in thyroid, breast, and other solid tumors. Cell-based and animal studies reveal that the liganded TRβ induces apoptosis, reduces an aggressive phenotype, decreases stem cell populations, and slows tumor growth through modulation of a complex interplay of transcriptional networks. TRβ-driven tumor suppressive transcriptomic signatures include repression of known drivers of proliferation such as PI3K/Akt pathway, activation of novel signaling such as JAK1/STAT1, and metabolic reprogramming in both thyroid and breast cancers. The presence of TRβ is also correlated with a positive prognosis and response to therapeutics in BRCA+ and triple-negative breast cancers, respectively. Ligand activation of TRβ enhances sensitivity to chemotherapeutics. TRβ co-regulators and bromodomain-containing chromatin remodeling proteins are emergent therapeutic targets. This review considers TRβ as a potential biomolecular diagnostic and therapeutic target.

17 September 2021 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
PDF file
EBEric L. Bolf
Eric L. Bolf
NGNoelle E. Gillis
Noelle E. Gillis
Cole DavidsonCole Davidson
Cole Davidson
LCLauren M. Cozzens
Lauren M. Cozzens
SKSophie Kogut
Sophie Kogut
FCFrances Carr
Frances Carr

1 June 2021 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
Cole DavidsonCole Davidson
Cole Davidson
EBEric L Bolf
Eric L Bolf
NGNoelle E Gillis
Noelle E Gillis
LCLauren M Cozzens
Lauren M Cozzens
JTJennifer A Tomczak
Jennifer A Tomczak
FCFrances Carr
Frances Carr
Thyroid cancer is the most common endocrine malignancy, and the global incidence has increased rapidly over the past few decades. Anaplastic thyroid cancer (ATC) is highly aggressive, dedifferentiated, and patients have a median survival of fewer than 6 months. Oncogenic alterations in ATC include aberrant phosphoinositide 3 kinase (PI3K) signaling through receptor tyrosine kinase (RTK) amplification, loss of phosphoinositide phosphatase expression and function, and protein kinase B (Akt) amplification. Furthermore, the loss of expression of the tumor suppressor thyroid hormone receptor beta (TRβ) is strongly associated with ATC. TRβ is known to suppress PI3K in follicular thyroid cancer and breast cancer by binding to the PI3K regulatory subunit p85α. However, the role of TRβ in suppressing PI3K signaling in ATC is not completely delineated. Here we report that TRβ indeed suppresses PI3K signaling in ATC cell lines through unreported genomic mechanisms, including a decrease in RTK expression and an increase in phosphoinositide and Akt phosphatase expression. Furthermore, the reintroduction and activation of TRβ in ATC cell lines enables an increase in the efficacy of the competitive PI3K inhibitors LY294002 and buparlisib on cell viability, migration, and suppression of PI3K signaling. These findings not only uncover additional tumor suppressor mechanisms of TRβ but shed light on the implication of TRβ status and activation on inhibitor efficacy in ATC tumors.

23 July 2021 in Preprints.org
Verified
Preprint
Open access
Cole DavidsonCole Davidson
Cole Davidson
NGNoelle E. Gillis
Noelle E. Gillis
FCFrances E. Carr
Frances E. Carr
There is compelling evidence that the nuclear receptor TRβ, a member of the thyroid hormone receptor (TR) family, is a tumor suppressor in thyroid, breast and other solid tumors. Cell-based and animal studies reveal that the liganded TRβ induces apoptosis, reduces an aggressive phenotype, decreases stem cell populations, and slows tumor growth through modulation of a complex interplay of transcriptional networks. TRβ-driven tumor suppressive transcriptomic signatures include repression of known drivers of proliferation such as PI3K/Akt pathway and activation of novel signaling (JAK1/STAT1) and metabolic reprogramming in both thyroid and breast cancers. The presence of TRβ is also correlated with a positive prognosis and response to therapeutics in BRCA+ and triple-negative breast cancers respectively. Ligand activation of TRβ enhances sensitivity to chemotherapeutics. TRβ co-regulators and bromodomain-containing chromatin remodeling proteins are emergent therapeutic targets. This review considers TRβ as a potential biomolecular diagnostic and therapeutic target.

31 August 2022 in Journal of Microbiology & Biology Education
Verified
Journal Article
Open access
Cole DavidsonCole Davidson
Cole Davidson
KHKarin Hodge
Karin Hodge
The recent increase in online learning modalities due to coronavirus disease 2019 (COVID-19) has created a significant gap in real-time discussions on complex issues. This lack of enrichment from student discussions levies the concern of a deficiency in strong learning outcomes.

Verified
Open access
HLHeather R Leek
Heather R Leek
AOAbby L Oberhelman
Abby L Oberhelman
SRSam R Rew
Sam R Rew
OJOlivia M Janss
Olivia M Janss
Cole DavidsonCole Davidson
Cole Davidson
JMJonathan Millen
Jonathan Millen
Pancreatic cancer accounts for approximately 8% of all cancer-related deaths. The compound cynaropicrin (CNP) has been investigated recently in several cancer models and has been shown to decrease cell viability. We used sulforhodamine B and trypan blue assays to measure cell viability following CNP treatment in PANC-1 cells. CNP reduced cell viability in a concentration-dependent manner (IC 50 = 5.29 µM) and significantly decreased free thiol levels. Finally, in silico docking demonstrated the potential for CNP to bind the DNA-binding domain of NF-κB. These data support further investigation of CNP as a potential therapeutic candidate in pancreatic cancer.